Acadian Asset Management LLC Avrobio, Inc. Transaction History

Acadian Asset Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$1.15 - $1.48 $250,154 - $321,938	-217,526 Reduced 14.96%	1,236,738 $1.58 Million
Q4 2023 Feb 13, 2024	SELL	$1.22 - $1.62 $330,406 - $438,736	-270,825 Reduced 15.7%	1,454,264 $1.98 Million
Q3 2023 Nov 13, 2023	SELL	$0.98 - $1.62 $44,156 - $72,993	-45,058 Reduced 2.55%	1,725,089 $2.66 Million
Q1 2023 May 11, 2023	BUY	$0.76 - $1.82 $228,193 - $546,464	300,255 Added 20.43%	1,770,147 $1.77 Million
Q4 2022 Feb 14, 2023	BUY	$0.64 - $0.91 $184,406 - $262,202	288,135 Added 24.38%	1,469,892 $1.05 Million
Q3 2022 Nov 14, 2022	BUY	$0.68 - $1.11 $39,571 - $64,594	58,193 Added 5.18%	1,181,757 $758,000
Q2 2022 Aug 09, 2022	BUY	$0.75 - $1.33 $157,580 - $279,442	210,107 Added 23.0%	1,123,564 $1.03 Million
Q1 2022 May 12, 2022	BUY	$1.29 - $4.04 $728,210 - $2.28 Million	564,504 Added 161.77%	913,457 $1.2 Million
Q4 2021 Feb 10, 2022	BUY	$3.45 - $6.05 $1.05 Million - $1.84 Million	304,609 Added 686.92%	348,953 $1.34 Million
Q3 2021 Nov 12, 2021	BUY	$5.53 - $9.28 $245,222 - $411,512	44,344 New	44,344 $246,000

559K

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Acadian Asset Management LLC with notifications on news.